Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis?

Dermatology

Volumn 198, Issue 2, 1999, Pages 198-202

  Paquet, P ^a   Pierard G E ^b  

^a CHU SART TILMAN   (Belgium)

^b NONE

Author keywords

Cyclosporin A; Toxic epidermal necrolysis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CASE REPORT; CELL POPULATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KERATINOCYTE; MACROPHAGE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS;

APOPTOSIS; CYCLOSPORINE; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; KERATINOCYTES; MACROPHAGES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0345620923     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018112     Document Type: Conference Paper

References (74)

1. Le Cleach L, Roujeau JC: Toxic epidermal necrolysis. J Dermatol Treat 1998;9:35-37.
2. Halebian P, Madden M, Finkelstein J, Corder V, Shires T: Improved burn center survival of patients with toxic epidermal necrolysis managed without corticoids. Ann Surg 1986;204: 503-512.
3. Ward DJ, Krzeminska EC, Tanner NSB: Treatment of toxic epidermal necrolysis and a review of six cases. Burns 1990;16:97-104.
4. Kelemen JJ, Cioffi WC, McManus WF, Mason AD, Pruitt BA: Burn center case for patients with toxic epidermal necrolysis. J Am Coll Surg 1995;180:173-178.
5. Revuz J, Penso D, Guillaume JC, Payne CR, Wechsler J, Touraine R: Toxic epidermal necrolysis: Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-1165.
6. Khoo AKM, Foo CL: Toxic epidermal necrolysis in a burn center: A 6-year review. Burns 1996;22:275-278.
7. Prendiville JS, Hebert AA, Greenwold MJ, Esterly N: Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989;115:881-887.
8. Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC: Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995;131:669-672.
9. Rzany B, Schmitt H, Schöpf E: Toxic epidermal necrolysis in patients receiving glucocorticoids. Acta Derm Venereol 1990;71:171-172.
10. Heng MCY, Allen SG: Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991;25:778-786.
11. Frangogiannes N, Boridy I, Mazhar M, Mathews R, Gangopathyay S, Cate T: Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 1996;89:1001-1003.
12. Redondo P, Ruiz de Erenchun F, Iglesias ME, Monedero P, Quintanilla E: Toxic epidermal necrolysis: Treatment with pentoxifylline. Br J Dermatol 1994;130:688-689.
13. Wolkenstein P, Latarget J, Roujeau JG, Duquet C, Boudeau S, Vaillant L, Maignan M, Milpied B, Bocquet H, Revuz J: Essai contrôlé du thalidomide dans la nécrolyse épidermique toxique. Ann Dermatol Vénéréol 1997;124 (suppl 1):S14.
14. Renfro L, Grant-Kels J, Daman L: Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989;28:441-444.
15. Zaki I, Patel S, Reed R, Dalziel KL: Toxic epidermal necrolysis associated with severe hypocalcaemia and treated with cyclosporin. Br J Dermatol 1995;133:337-338.
16. Jarrett P, Rademaker M, Havill J, Pullon H: Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 1997;22:146-147.
17. Jarrett P, Ha T, Snow J: Toxic epidermal necrolysis and cyclosporin. Clin Exp Dermatol 1997;22:250-256.
18. Merot Y, Gravallesse E, Guillen F, Murphy G: Lymphocyte subsets and Langerhans cells in toxic epidermal necrolysis. Arch Dermatol 1986;122:455-458.
19. Miyauchi H, Hosokawa H, Akaeda T, Iba H, Asada Y: T-cell subsets in drug-induced toxic epidermal necrolysis. Arch Dermatol 1991; 127:851-855.
20. Villada G, Roujeau JC, Clerici T, Bourgault I, Revuz J: Immunopathology of toxic epidermal necrolysis. Arch Dermatol 1992;128:50-53.
21. Friedmann PS, Strickland I, Pirmohamed M, Park K: Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994;130:598-604.
22. Paquet P, Nikkels A, Arrese J, Vanderkelen A, Piérard GE: Macrophages and tumor necrosis factor α in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-608.
23. Paquet P, Piérard GE: Soluble fractions of tumor necrosis factor-α, interleukin-6 and of their receptors in toxic epidermal necrolysis: A comparison with second-degree burns. Int J Mol Med 1998;1:458-462.
24. Nickoloff BJ, Griffiths CEM, Barker JNWN: The role of adhesion molecules, chemotactic factors and cytokines in inflammatory and neoplastic skin disease - 1990 update. J Invest Dermatol 1990;94:15IS-157S.
25. Nestlé FO, Filgueira L, Nickoloff BJ, Burg G: Human dermal dendritic cells process and present soluble protein antigens. J Invest Dermatol 1998;110:762-766.
26. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, Roujeau JC: Apoptosis as a mechanism of keratinocyle death in toxic epidermal necrolysis. Br J Dermatol 1996;134: 710-714.
27. Wyllie AH: Apoptosis: An overview. Br Med Bull 1997;53:451-465.
28. Reynolds NJ, Voorhees JJ, Fisher G: Cyclosporin A inhibits 12-O-tetradecanoyl-phorbol-13-acetate induced cutaneous inflammation in severe combined immunodeficient mice that lack functional lymphocytes. Br J Dermatol 1998;139:16-22.
29. Griffiths CE, Fisher GJ, Harding MW: Cyclophilin content of normal and psoriatic epidermis. J Invest Dermatol 1990;94:436-440.
30. Gupta AK, Fisher GJ, Elder JT: Topical cyclosporin A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. J Invest Dermatol 1989;93:379-386.
31. Cooper KD, Baadsgaard O, Ellis CN: Mechanisms of cyclosporin A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol 1990; 94:649-656.
32. Holschermann H, Durfeld F, Maus U, Bierhaus A, Heidinger K, Lohmeyer J, Nawroth PP, Tillmanns H, Haberbosch W: Cyclosporin A inhibits tissue factor expression in monocytes/ macrophages. Blood 1996;88:3837-3845.
33. Hattori Y, Nakanishi N: Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopherin synthesis in bacterial lipopolysaccharide-treated J774 macrophages. Cell Immunol 1995;165:7-11.
34. Rezzani R, Rodella L, Milanesi S, Bianchi R: Immunohistochemical characterization of thymic macrophages in normal and treated rats: A differential sensitivity to cyclosporin A. Int J Exp Pathol 1996;77:191-196.
35. Svensson U, Holst E, Sundler R: Cyclosporin-sensitive expression of cytokine mRNA in mouse macrophages responding to bacteria. Mol Immunol 1995;32:157-165.
36. Geratz JD, Pryzwansky KB, Anderle SK, Tidwell RR: Control of glucan-induced systemic granulomatosis by cyclosporin A. Inflammation 1995;19:221-231.
37. Pimentel-Munos FX, Mezana J, Fresno M: Regulation of interleukin-2 receptor alpha chain expression and nuclear factor kappa B activation by protein kinase C in T lymphocytes: Autocrine role of tumor necrosis factor alpha. J Biol Chem 1994;269:24424-24429.
38. Briggs WA, Gao ZH, Xing JJ, Scheel PJ, Gimenez LF, Samaniego MD, Choi MJ, Burdick JF: Suppression of dialysis patients' lymphocyte IL-2R expression by glucocorticoids and cyclosporing. Cytokine 1997;9:624-628.
39. McConkey D, Orrenius S: The role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun 1997;239:357-366.
40. Maksymowicz M, Olszewski WL: Cyclosporin control of recipient lymphocyte traffic to the heart allograft. Transplant Proc 1996;28:3441-3443.
41. Cockerell GW, Berth AG, Ryan GR, Gamble JR, Vadas MA, Cockerell PN: Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood 1995;86:2689-2698.
42. +)-adenosine triphosphatase is a possible mechanism of immunosuppressive activity of cyclosporin A. Mol Pharmacol 1993;44:605-614.
43. Briggs WA, Gao ZH, Xing JJ, Scheel PJ, Gimenez LF, Choi MJ, Burdick JF: Differential suppression of dialysis patients' lymphocyte IFN-gamma production by glucocorticoids and cyclosporin. Cytokine 1996;8:804-808.
44. Frishberg Y, Meyers CM, Kelly CJ: Cyclosporine A regulates T cell-epithelial cell adhesion by altering LFA-1 and ICAM-1 expression. Kidney Int 1996;50:45-53.
45. Van Besauw NM, Vaessen LM, Balk AH, Mochtar B, Claas FH, Weimar W: CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipients. Transplant Proc 1996;28:3135-3136.
46. Deneckers G, Vandenabeele P, Groden J, Penning LC, DeClercq W, Beyaert R, Buurman WA, Fiers W: Differential role of calcium in tumour necrosis factor-mediated apoptosis and secretion of granulocyte-macrophage colony-stimulating factor in a T-cell hybridoma. Cytokine 1997;9:631-638.
47. Leithauser ML, Rob PM, Sack K: Pentoxifylline, cyclosporin A and taurolidine inhibit endotoxin-stimulated tumor necrosis factor-alpha production in rat mesangial cell culture. Exp Nephrol 1997;5:100-104.
48. Pastorino JG, Simbula G, Yamamoto K, Glascott PA, Rothman RJ, Farber JL: The cytotoxiity of tumor necrosis factor depends on induction of the mitochrondrial permeability transition. J Biol Chem 1996;271:29792-29798.
49. Marionnet AV, Chardonnet Y, Viac J, Schmitt D: Differences in responses of interleukin-1 and tumor necrosis factor alpha production and secretion to cyclosporin A and ultraviolet B irradiation by normal and transformed keratinocyte cultures. Exp Dermatol 1997;6:22-28.
50. Dawson J, Hurtenbach U, MacKenzie A: Cyclosporin A inhibits the in vivo production of interleukin-1 beta and tumour necrosis factor alpha, but not interleukin-6 by a T-cell independent mechanism, Cytokine 1996;8:882-888.
51. Ciesielski CJ, Mei J, Neton JT, Peccinini CA: Effects of cyclosporin A and methotrexate on induction of tumour necrosis factor alpha in rat cardiac allografts. Transplant Immunol 1997;5:25-34.
52. Le Contel C, Beigneux AP, Huan J, Parant MA: Regulation of lipopolysaccharide-induced tumor necrosis factor production by cyclosporin A in mice primed with muranyl dipeptide. FEMS Immunol Med Microbiol 1995;11:297-305.
53. Kono T, Kondo S, Venner TJ, Sauder DN, McKenzie RC: Inhibition of cytokine gene expression in mouse skin by subcutaneous injection of cyclosporin. Skin Pharmacol 1995;8: 149-155.
54. Meyer S, Kohler NG, Joly A: Cyclosporin A is an uncompetitive inhibitor of proteasone activity and prevents NF-kappa B activation. FEBS Lett 1997;413:354-358.
55. Shatrov VA, Lehmann V, Chouaib S: Sphinogosine-1-phosphate mobilizes intracellular calcium and activates transcription factor NF-kappa B in U937 cells. Biochem Biophys Res Commun 1997;234:121-124.
56. Yazdanbakhsh K, Choi JW, Li Y, Lau LF, Choi Y: Cyclosporin A blocks apoptosis by inhibiting the DNA binding activity of the transcription factor Nur 77. Proc Natl Acad Sci USA 1995;92:437-441.
57. Yokoyama I, Hayakawa A, Hayashi S, Kobayashi T, Negita M, Takagi H: Fas antigen expression of hepatocytes and its modification by immunosuppressants. Dig Dis Sci 1997;42: 2471-2475.
58. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM: The CD95 (APO-1/FAS) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57:3823-3829.
59. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-493.
60. Genestier L, Bonnefoy-Berard N, Rouault JP, Flacher M, Revillard JP: Tumor necrosis factor-alpha up-regulates Bcl-2 expression and decreases calcium-dependent apoptosis in human B cell lines. Int Immunol 1995;7:533-540.
61. Labalette M, Queyrel V, Masy E, Noel C, Pruvot FR, Dessaint JP: Implication of cyclosporin in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients. Transplantation 1995;59:1714-1723.
62. Zamzani n, Marchetti P, Casledo M, Hirsch T, Susin SA, Masse B, Kroemer G: Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett 1996; 384:53-57.
63. Sullivan JR, Watson A: Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: A discussion of pathogenesis and immunosuppressive management. Aust J Dermatol 1996;37:208-212.
64. Paquet P, Piérard GE: Breast and lung cancers in two cyclosporin-A-treated psoriatic women. Dermatology 1998;196:450-452.
65. Al Rustom K, Piérard-Franchimont C, Piérard GE: Présentation clinique et histologique de la maladie du greffon contre l'hôte traitée par cyclosporine A. Dermatologica 1985;171:65-71.
66. Wüthrich RP, Sekar P: Effect of dexamethasone, 6-mercaptopurine and cyclosporin A on intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression. Biochem Pharmacol 1993;46:1349-1353.
67. Dogan A, MacDonald TT, Spencer J: Cyclosporin A enhances T-cell-mediated induction of E-selectin. Eur J Immunol 1993;23:2922-2926.
68. Cockfield SM, Ramassar U, Halloran PF: Regulation of IFN-gamma and tumor necrosis factor-alpha expression in vivo: Effects of cycloheximide and cyclosporin in normal and lipopolysaccharide-treated mice. J Immunol 1993;150:342-352.
69. Kitagaki K, Niwa S, Hoshiko K, Nagai H, Hayashi S, Totsuka T: Augmentation of apoptosis in bronchial exuded rat eosinophils by cyclosporin A. Biochem Biophys Res Commun 1996;222:71-77.
70. Belshaw PJ, Spencer DM, Crabtree GR, Schrieber SL: Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Chem Biol 1996;3:731-738.
71. 2+ elevation and cyclosporin A synergistically induce TGF-beta-1-mediated apoptosis in lymphocytes. J Immunol 1997;158:2527-2534.
72. Mosieniak G, Figiel I, Kaminska B: Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J Neurochem 1997;68:1142-1149.
73. Horigone A, Hirano T, Oka T, Takeuchi H, Sakurai E, Kozaki K, Matsuno N, Nagao T, Kozaki M: Glucocorticoids and cyclosporin induce apoptosis in mitogen-activated human peripheral mononuclear cells. Immunopharmacology 1997;37:87-94.
74. Ito C, Ribeiro RC, Behm FG, Raimondi SC, Pui CH, Capana D: Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 1998;91:1001-1007.